Yan Leyfman: Turning Paradoxical Biology Into Precision Immunotherapy Opportunities
Yan Leyfman, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn, about a recent article by Nicholas J. Salgia published in Cancer Cell.
“Renal cell carcinoma with sarcomatoid features (sRCC) is aggressive yet unusually sensitive to immune checkpoint blockade (ICB).
Using single-cell, spatial, and bulk transcriptomic analyses (>3,000 RCC tumors), authors found:
- Highly activated but exhausted T cells enriched for CXCL13
- Abundant tertiary lymphoid structures and humoral immune activity
- Iron-associated tumor programs — a potential therapeutic target
- A genomic dedifferentiation signature (GDS) that predicts ICB benefit across cancers despite poor prognosis
Turning paradoxical biology into precision immunotherapy opportunities.”
Title: Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma
Authors: Nicholas J. Salgia, Adil Khan, Wilhelm M. Aubrecht, Gavin C. Twoey, Jacky Chow, Kristopher Attwood, Han Yu, Jessie L. Chiello, Nathaniel Hansen, Brianna J. Wasik, Benjamin D. Mercier, Hedyeh Ebrahimi, Luis Meza, Orla Maguire, Michalis Mastri, Cassandra Whalen, Hans Minderman, Patrick Pirrotte, Sara Byron, Elizabeth A. Repasky, Jason B. Muhitch
Read The Full Article at Cancer Cell.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023